On Friday, Shares of Encana Corporation (NYSE:ECA), gained 1.03% to $6.86.
Encana Corporation - David Hill, Executive Vice President of Exploration and Business Development, will be presenting at Enercom’s The Oil and Gas Conference on Tuesday, August 18, 2015 at about 1:30 p.m. MDT (3:30 p.m. EDT) in Denver, Colorado.
Encana Corporation, together with its auxiliaries, engages in the development, exploration, production, and marketing of natural gas, oil, and natural gas liquids in Canada and the United States.
Shares of Seagate Technology Public Limited Company (NASDAQ:STX), inclined 1.27% to $52.02, during its last trading session.
LaCie, the premium brand from Seagate Technology Public Limited Company revealed a series of sketches and stories from well-known designer Neil Poulton to commemorate the tenth anniversary of its Rugged™ drive. In an infographic, LaCie™ shared the evolution of its iconic hard drive, from the birth of the concept in 2005, to its surge in popularity with Apple® users, to its ubiquity on movie sets and photo shoots.
For the first time, Poulton shared the painstaking process behind the original design. This comprised of countless revisions and some of the challenges with early design concepts. Poulton also looked back at his inspirations for the product designs, counting the Spectrum Pursuit Vehicle, the tank-like vehicle from the 1967 TV show Captain Scarlet and the Mysterons, and a basketball.
LaCie highlighted the Rugged drive’s tech milestones, showing how this product has been consistently a step ahead of the storage industry. Key indicators comprise leading speeds and capacities, the latest interfaces, and even biometric access. From 80 GB to 4 TB of capacity and from USB 2.0 to Thunderbolt™, Rugged drive’s history showcases the fascinating evolution of digital storage.
Seagate Technology Public Limited Company designs, manufactures, and sells electronic data storage products in the Asia Pacific, the Americas, and EMEA countries.
Finally, Relypsa, Inc. (NASDAQ:RLYP), ended its last trade with 4.49% gain, and closed at $24.89.
Relypsa declared it has entered a two-year detailing agreement with Sanofi for Patiromer for Oral Suspension (Patiromer FOS). Patiromer FOS is Relypsa’s investigational medicine that is presently under review for the treatment of hyperkalemia with the U.S. Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) action date of October 21, 2015.
Relypsa intends to commercialize Patiromer FOS, if approved, with its own dedicated U.S.-based commercial team and specialty sales force of about 120 sales representatives. Relypsa’s sales force will focus primarily on outreach to nephrologists, cardiologists and hospitals. Under the terms of the agreement, Sanofi’s nephrology sales force will complement Relypsa’s efforts by detailing Patiromer FOS in the United States for a two-year period. During the term of the agreement, Sanofi will be paid a service fee and is also eligible to receive incentive payments. The term may be extended by mutual agreement of both parties.
Relypsa will continue to be responsible for all regulatory, development, commercial, manufacturing and distribution activities for Patiromer FOS in the United States, counting recording sales.
Relypsa, Inc., a biopharmaceutical company, focuses on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases in the United States. Its lead product candidate comprises Patiromer, a non-absorbed potassium binding polymer that accomplished Phase III clinical trial for the treatment of hyperkalemia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
